CDK6 Overexpression

CI-VAR-00003150Explore in graph →CIViC 602

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
CDK6 Overexpression	Palbociclib	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11200 The PALOMA-3 trial compared palbociclib plus fulvestrant vs placebo plus fulvestrant and evaluated molecular correlates of response in 302 patients with metastatic breast cancer. mRNA expression level… (full text at CIViC) PMID 30807234 · Turner et al., 2019 · Open in CIViC	civic
Childhood B-cell Acute Lymphoblastic Leukemia1unmapped disease
CDK6 Overexpression	Dexamethasone + RibociclibCombination	Predictive	D	Supports Sensitivity Response	3	rejected	EID8113 CDK6 was found to be significantly overexpressed in the bone marrow of B-ALL patients (n=299) compared to normal bone marrow (n=74, p<.001). Combination treatment with dexamethasone (glucocorticoid) a…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Estrogen Receptor-positive Breast Cancer2unmapped disease
CDK6 Overexpression	Fulvestrant	Predictive	B	Supports Resistance	4	accepted	EID1526 In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months an… (full text at CIViC) PMID 27252418 · Alves et al., 2016 · Open in CIViC	civic
CDK6 Overexpression	Fulvestrant + PalbociclibCombination	Predictive	D	Supports Sensitivity Response	2	accepted	EID1527 Four fulvestrant (estrogen receptor degrader) resistant cell lines were derived from parent fulvestrant sensitive ER+ MCF-7/SO.5 breast cancer cell line. Derivative cell lines showed some sensitivity … (full text at CIViC) PMID 27252418 · Alves et al., 2016 · Open in CIViC	civic

Glioblastoma Proneural Subtype1unmapped disease
CDK6 Overexpression	Palbociclib	Predictive	D	Supports Sensitivity Response	2	accepted	EID7800 In this study twelve GBM cell lines and normal human astrocytes (NHA) were treated with the CDK4/6 inhibitor palbociclib. NHA and several GBM cell lines were resistant to palbociclib with IC50 values … (full text at CIViC) PMID 28903422 · Li et al., 2017 · Open in CIViC	civic